Expansion of Buprenorphine Treatment via Telemedicine Encounter

Summary

The US Drug Enforcement Administration and Department of Health and Human Services are amending regulations to expand telemedicine access to schedule III-V controlled substances for opioid use disorder treatment, allowing initial six-month supplies via audio-only telemedicine.